We seek to advance highly specialised and scientifically valuable fields to elevate the standard of healthcare.

Discover more about Menarini Group

For over 30 years, Menarini has been driving research and development to deliver innovative and effective medicines and healthcare solutions for patients affected by serious health conditions.

Gain a single point of entry to all major APAC markets with a direct presence in 13 key markets.

Sharing your partnering idea

Leverage our omni-channel approach to grow your brand across Asia Pacific.


The healthcare sector in Asia Pacific is rapidly growing. As part of the world’s leading Italian biopharmaceutical company, Menarini AP has a strong presence in 13 key markets across the region.

As a partner of choice for numerous global healthcare companies, we engage in the entire pharmaceutical development lifecycle to tap growth opportunities and grow their brand footprint. In doing so, we also support healthcare professionals and patients with quality medical products and technology to raise standards and invigorate lives for tomorrow.

Our APAC Headquarters


30 Pasir Panjang Road,
Mapletree Business City,
#08-32 Singapore 117440
Tel: +65-6494-7200
Fax: +65-6999-1787




  • 2021 - 12 - 23

    Karyopharm and Menarini Group Enter into Exclusive License Agreement to Commercialize NEXPOVIO® (selinexor) in Europe and Other Key Global Territories

    Menarini Group Obtains Exclusive Rights to Commercialize NEXPOVIO for the Treatment of Hematologic and Solid Tumor Oncology Indications in Europe (including the United Kingdom), Latin America and Other Key Countries
  • 2021 - 11 - 04

    Menarini Receives FDA Orphan Drug Designation for SEL24/MEN1703, a first in class, dual PIM/FLT3 inhibitor for the Treatment of Acute Myeloid Leukemia

    Florence (Italy) November 4th, 2021 – The Menarini Group announced today that the U.S. Food and Drug Administration (FDA) granted orphan drug designation (ODD) to SEL24/MEN1703 for the treatment of Acute Myeloid Leukemia (AML). SEL24/MEN1703 is a first-in-class, orally available, dual PIM/FLT3 inhibitor, in-licensed by Menarini from Ryvu Therapeutics, and currently investigated in the DIAMOND-01 trial as a single agent for the treatment of patients with relapsed/refractory AML.
  • 2021 - 10 - 20

    Menarini Group and Radius Health Announce Positive Phase 3 Topline Results from the EMERALD Trial Evaluating Elacestrant in Breast Cancer

    Florence, Italy and Boston, Mass., October 20, 2021 – the Menarini Group (“Menarini”) and Radius Health, Inc. (“Radius”) (NASDAQ: RDUS) (collectively, the “Companies”) today announced positive topline results from the EMERALD study.
  • 2021 - 08 - 22

    Menarini Enters into an Exclusive Licensing Agreement with Daiichi Sankyo to Commercialise TARLIGE® in Singapore, Malaysia, and the Philippines

    Singapore, 23 August, 2021 - A. Menarini Asia-Pacific Holdings Pte. Ltd., part of the leading Italian global biopharmaceutical company Menarini Group, signed a multi-year exclusive licensing agreement to assume the registration, sales, marketing, and distribution of the orally administered gabapentinoid, mirogabalin (brand name; TARLIGE®), in the Philippines, Malaysia and Singapore.
  • 2021 - 07 - 21

    Menarini Asia-Pacific strengthens Men’s Health portfolio in China with acquisition of Cialis® (Tadalafil) from Lilly

    22/07/21, Singapore – A. Menarini Asia-Pacific Holdings Pte. Ltd., part of the Menarini Group, the world’s largest Italian biopharmaceutical company, announced today the completion of its acquisition of Cialis® in the People’s Republic of China from Eli Lilly and Company. Through the acquisition, Menarini will take over ownership of the brand and assume all sales, marketing and distribution responsibilities.
  • 2021 - 04 - 08

    Menarini Pills of Art Junior project launched, video clips made by the younger generations for children and teenagers

    Florence, Italy, 9th April 2021. “Who are the people depicted in the Primavera and why are they dancing in an orchard instead of a ballroom? “or “ Why was the Medusa painted on a shield?” These are just some of the questions posed by the young protagonists of the Pills of Art Junior series, now online in Italian and English on the Menarini Group YouTube channel, aimed at getting the younger generations interested in some of the world’s timeless masterpieces.